Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry

J Crohns Colitis. 2018 May 25;12(6):695-701. doi: 10.1093/ecco-jcc/jjy017.

Abstract

Background: Intra-abdominal abscesses [IAAs] are common life-threatening complications in patients with Crohn's disease [CD]. In addition to interventional drainage and surgical therapy, empirical antibiotic therapy represents a cornerstone of treatment, but contemporary data on microbial spectra and antimicrobial resistance are scarce.

Methods: We recruited 105 patients with CD and IAAs from nine German centres for a prospective registry in order to characterize the microbiological spectrum, resistance profiles, antibiotic therapy and outcome.

Results: In 92 of 105 patients, microbial investigations of abscess material revealed pathogenic microorganisms. A total of 174 pathogens were isolated, with a median of 2 pathogens per culture [range: 1-6]. Most frequently isolated pathogens were E. coli [45 patients], Streptococcus spp. [28 patients], Enterococci [27 patients], Candida [13 patients] and anaerobes [12 patients]. Resistance to third-generation cephalosporins, penicillins with beta-lactamase inhibitors and quinolones were observed in 51, 36 and 35 patients, respectively. Seven patients had multiple-drug-resistant bacteria. Thirty patients received inadequate empirical treatment, and this was more frequent in patients receiving steroids or immunosuppression [37%] than in patients without immunosuppression [10%: p = 0.001] and was associated with a longer hospital stay [21 days vs 13 days, p = 0.003].

Conclusion: Based on antimicrobial resistance profiles, we herein report a high rate of inadequate empirical first-line therapy for IAAs in CD, especially in patients receiving immunosuppression, and this is associated with prolonged hospitalization.

Publication types

  • Multicenter Study

MeSH terms

  • Abdominal Abscess / drug therapy*
  • Abdominal Abscess / microbiology*
  • Adult
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Antifungal Agents / therapeutic use
  • Candida albicans / isolation & purification
  • Carbapenems / therapeutic use
  • Cephalosporins / therapeutic use
  • Crohn Disease / complications*
  • Crohn Disease / drug therapy
  • Drug Resistance, Multiple, Bacterial
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae / isolation & purification*
  • Enterococcus / drug effects
  • Enterococcus / isolation & purification
  • Female
  • Germany
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Intestinal Perforation / complications*
  • Length of Stay
  • Levofloxacin / therapeutic use
  • Male
  • Penicillins / therapeutic use
  • Prospective Studies
  • Quinolones / therapeutic use
  • Registries
  • Streptococcus / drug effects
  • Streptococcus / isolation & purification
  • Young Adult
  • beta-Lactamase Inhibitors / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Carbapenems
  • Cephalosporins
  • Immunosuppressive Agents
  • Penicillins
  • Quinolones
  • beta-Lactamase Inhibitors
  • Levofloxacin